Firas Bassissi

Firas Bassissi has a significant amount of work experience in the pharmaceutical industry. Firas has held various leadership positions throughout their career. Their most recent role was as the Chief Scientific Officer at XENOTHERA, starting in May of 2023. Prior to that, they served as the Vice President of Research and Development at SANIFIT Therapeutics/CSL Vifor, starting in July of 2018. From 2012 to 2018, they worked as the Chief Scientific Officer and Chief Development Officer at Genoscience Pharma, where they were responsible for developing screening strategies and lead selection for anticancer agents. From 2009 to 2012, Firas worked as a Team Leader in Preclinical Candidate Selection at AbbVie. Before that, from 2007 to 2009, they held the role of Head of Pharmacokinetics and Toxicology Development at Trophos/Roches. Firas started their career in 2002 as a Researcher in Pharmacokinetics and Toxicology at INRA, where they focused on studying the effects of lipids on drug transport and bioavailability. Throughout their career, Firas has gained experience in project management, regulatory affairs, clinical and preclinical studies, and pharmacokinetics.

Firas Bassissi has an extensive education history. Firas obtained their Doctor degree in Veterinary Medicine from Veterinary School, where they studied from 1992 to 1997. Afterward, in 2001, they pursued further education in Animal Sciences, completing a Master II degree at the Institut national polytechnique de Lorraine in 2002. Following this, from 2003 to 2006, Firas pursued a PhD in Pharmacokinetics and Toxicology at the Université Paul Sabatier Toulouse III. Firas also completed a post-graduate degree in Pharmacokinetics at the same institution from 2004 to 2005. In 2022, Firas attended HEC Paris, where they pursued an Executive Master degree in Innovation and Entrepreneurship, completing their studies in 2023.